Literature DB >> 4183134

Autoantibodies in patients with vitiligo.

J Brostoff.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1969        PMID: 4183134     DOI: 10.1016/s0140-6736(69)91421-4

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  11 in total

Review 1.  Autoimmune polyglandular syndrome type 1.

Authors:  P Obermayer-Straub; C P Strassburg; M P Manns
Journal:  Clin Rev Allergy Immunol       Date:  2000-04       Impact factor: 8.667

2.  Microbial skin flora of selected cancer patients and hospital personnel.

Authors:  M E McBride; W C Duncan; G P Bodey; C M McBride
Journal:  J Clin Microbiol       Date:  1976-01       Impact factor: 5.948

3.  Addison's disease, vitiligo and multiple autoantibodies.

Authors:  C J Burns-Cox; J E Pearson
Journal:  Postgrad Med J       Date:  1972-02       Impact factor: 2.401

4.  Clinical associations of vitiligo.

Authors:  R P Dawber
Journal:  Postgrad Med J       Date:  1970-05       Impact factor: 2.401

Review 5.  Vitiligo in adults and children: surgical interventions.

Authors:  Rubeta Matin
Journal:  BMJ Clin Evid       Date:  2015-03-20

Review 6.  Vitiligo in adults and children.

Authors:  Rubeta Matin
Journal:  BMJ Clin Evid       Date:  2011-03-28

7.  Vitiligo- and melanoma-associated hypopigmentation: a similar appearance but a different mechanism.

Authors:  O Merimsky; Y Shoenfeld; G Yecheskel; S Chaitchik; E Azizi; P Fishman
Journal:  Cancer Immunol Immunother       Date:  1994-06       Impact factor: 6.968

Review 8.  Vitiligo.

Authors:  Rubeta Matin
Journal:  BMJ Clin Evid       Date:  2008-04-18

Review 9.  The clinical significance of antityrosinase antibodies in melanoma and related hypopigmentary lesions.

Authors:  O Merimsky; Y Shoenfeld; P Fishman
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

10.  Relapse after methylprednisolone oral minipulse therapy in childhood vitiligo: a 12-month follow-up study.

Authors:  Imran Majid; Saher Imran
Journal:  Indian J Dermatol       Date:  2013-03       Impact factor: 1.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.